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sBACKGROUND: The TP53 pathway, in which TP53 and its negative regulator MDM2 are the central elements, has an important role in
carcinogenesis, particularly in BRCA1- and BRCA2-mediated carcinogenesis. A single nucleotide polymorphism (SNP) in the promoter
region of MDM2 (309T4G, rs2279744) and a coding SNP of TP53 (Arg72Pro, rs1042522) have been shown to be of functional
significance.
METHODS: To investigate whether these SNPs modify breast cancer risk for BRCA1 and BRCA2 mutation carriers, we pooled genotype
data on the TP53 Arg72Pro SNP in 7011 mutation carriers and on the MDM2 309T4G SNP in 2222 mutation carriers from the
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Data were analysed using a Cox proportional hazards model within a
retrospective likelihood framework.
RESULTS: No association was found between these SNPs and breast cancer risk for BRCA1 (TP53: per-allele hazard ratio (HR)¼1.01,
95% confidence interval (CI): 0.93–1.10, Ptrend¼0.77; MDM2:H R¼0.96, 95%CI: 0.84–1.09, Ptrend¼0.54) or for BRCA2 mutation
carriers (TP53:H R¼0.99, 95%CI: 0.87–1.12, Ptrend¼0.83; MDM2:H R¼0.98, 95%CI: 0.80–1.21, Ptrend¼0.88). We also evaluated
the potential combined effects of both SNPs on breast cancer risk, however, none of their combined genotypes showed any
evidence of association.
CONCLUSION: There was no evidence that TP53 Arg72Pro or MDM2 309T4G, either singly or in combination, influence breast
cancer risk in BRCA1 or BRCA2 mutation carriers.
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The TP53 pathway is crucial for tumour suppression, acting
through regulation of cell-cycle control, apoptosis, senescence and
DNA repair. The TP53 gene and its negative regulator MDM2
are central to this pathway, promoting polyubiquitination and
degradation of TP53, and also controlling the TP53 synthesis
(Toledo and Wahl, 2006; Candeias et al, 2008). Inactivation of the
TP53 pathway has an important role in BRCA1- and BRCA2-
associated tumourigenesis. BRCA1 and BRCA2 mutations are
associated with genomic instability caused by defective cell-cycle
checkpoint and DNA damage repair (Deng, 2006). Mouse model
studies have highlighted functional links between these genes.
Biallelic inactivation of BRCA1 and BRCA2 in mice have shown
that embryonic lethality because of growth retardation can be
partially rescued in a Trp53 null background (Evers and Jonkers,
2006). The development of mammary tumours in conditional
BRCA1 and BRCA2 knockout mice was considerably accelerated
in a Trp53 knockout background (Evers and Jonkers, 2006). In
addition, a high incidence of TP53 mutations has been found
in breast tumours of human BRCA1 and BRCA2 mutation carriers
(Greenblatt et al, 2001; Manie et al, 2009). The observed
interactions between TP53 and BRCA pathways are integral to
the progression of tumourigenesis in breast cancer.
A TP53 polymorphism (rs1042522) has been found to be of
functional significance, with the Pro72 allele being less efficient
than Arg72 at inducing apoptosis, mainly due to weaker binding
and ubiquitination by MDM2 of the Pro72 variant protein
(Dumont et al, 2003; Osorio et al, 2006). An SNP in the promoter
region of MDM2 (309T4G, rs2279744) has been shown to increase
MDM2 transcriptional activity, thus attenuating the TP53 pathway
(Bond et al, 2004). This latter SNP was associated with an earlier
onset of breast cancer in Li–Fraumeni patients carrying TP53
mutations (Bougeard et al, 2006; Ruijs et al, 2007). The effect on
breast cancer risk of the TP53 Arg72Pro and the MDM2 309T4G
polymorphisms, separately and in combination, was investigated
in a large case–control study by the Breast Cancer Association
Consortium (BCAC), but no association was detected (Schmidt
et al, 2007). However, several smaller studies examined these
polymorphisms in BRCA1 and BRCA2 mutation carriers (Martin
et al, 2003; Tommiska et al, 2005; Copson et al, 2006; Osorio et al,
2006; Wasielewski et al, 2007; Yarden et al, 2008), and some
suggested an association between the TP53 Pro72 and the MDM2
309G alleles with an earlier age at breast cancer diagnosis (Martin
et al, 2003; Tommiska et al, 2005; Osorio et al, 2006; Yarden et al,
2008). We therefore investigated the associations between breast
cancer risk and these TP53 and MDM2 polymorphisms in a large
series of BRCA1 and BRCA2 mutation carriers from the
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
(Chenevix-Trench et al, 2007).
MATERIALS AND METHODS
Study sample
Eligibility was restricted to female carriers with pathogenic
mutations in BRCA1 or BRCA2 who were X18 years. Data were
obtained from 13 CIMBA studies (Table 1). The majority of
carriers were recruited through cancer genetics clinics offering
genetic testing, and enrolled into national or regional studies.
Information collected included the year of birth; mutation
description; age at last followup; ages at breast and ovarian cancer
diagnosis; and age at bilateral prophylactic mastectomy. Informa-
tion was also available on the country of residence, which was
defined to be the country of the clinic at which the carrier family
was recruited for the study. Related individuals were identified
through a unique family identifier. Further details of the
information collected on the BRCA1 and BRCA2 mutation carriers
and other details of the CIMBA initiative can be found elsewhere.
Additional specific acknowledgements to the CIMBA collaborating
centres are included in the Supplementary Appendix. (http://
www.srl.cam.ac.uk/consortia/cimba/index.html) (Chenevix-Trench
et al, 2007). All carriers participated in clinical and research
studies at the host institutions under IRB-approved protocols.
Genotyping
We pooled genotype data from studies within CIMBA that had
previously genotyped polymorphisms rs1042522 and rs2279744
(see Table 1). Deviation from Hardy–Weinberg equilibrium
among unrelated subjects was evaluated separately for each SNP
and study. There was evidence for deviation for only one study
(P¼0.03), but cluster plot examination did not show any unusual
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study specific genotyping quality control data were examined and
data were included if the call rate was over 95% and the
concordance among duplicates was over 98%.
Statistical analysis
Mutation carriers were classified according to their age at
diagnosis of breast cancer or their age at last follow up. For this
purpose, individuals were censored at the age of first breast cancer
diagnosis, ovarian cancer diagnosis, bilateral prophylactic mas-
tectomy or the age at last observation. Only individuals censored at
breast cancer diagnosis were assumed to be affected (Table 2).
To correct for a potential bias related to the fact that BRCA1 and
BRCA2 mutation carriers are not randomly sampled with respect
to their disease status, the data were analysed within a survival
analysis framework, by modelling the retrospective likelihood of
the observed genotypes conditional on the disease phenotypes. A
detailed description of the retrospective likelihood approach has
been published (Antoniou et al, 2007). We used a Cox proportional
hazards model, where the effect of each SNP was modelled either
as a per-allele hazard ratio (HR) or using separate HRs for
heterozygotes and homozygotes. To assess the combined effects of
the SNPs, we fitted a model in which a separate HR parameter was
estimated for each multilocus genotype. More details of the
statistical analysis can be found elsewhere (Antoniou et al, 2008).
RESULTS
In total, 7011 BRCA1 and BRCA2 mutation carriers were genotyped
for TP53 Arg72Pro and 2222 mutation carriers were genotyped
for MDM2 309T4G (Table 1). Table 2 shows summary statistics
for the cohort of BRCA1 and BRCA2 mutation carriers with an
observed genotype for either the TP53 or MDM2 polymorphism.
There was no evidence of an association between either SNP and
breast cancer risk in BRCA1 or BRCA2 mutation carriers combined
or analysed separately (TP53 Arg72Pro: Ptrend¼0.89, 0.77 and 0.83,
respectively; MDM2 309T4G: Ptrend¼0.60, 0.54 and 0.88, respec-
tively) (Table 3). There was no evidence for heterogeneity in the
HRs between studies (TP53 Arg72Pro: P¼0.22 and 0.93, MDM2
309T4G: P¼0.11 and 0.82 for BRCA1 or BRCA2 mutation carriers
respectively). The HRs for the 9 TP53–MDM2 combined
genotypes, estimated separately in BRCA1 and BRCA2 mutation
carriers, ranged between 0.72 and 1.31, but none of them were
significant.
DISCUSSION
To our knowledge, this is the largest study to investigate the
hypothesis that TP53 Arg72Pro and MDM2 309T4G influence
breast cancer risk in BRCA1 and BRCA2 mutation carriers
individually or in combination. Our findings of no association
Table 1 Number of BRCA1 and BRCA2 mutation carriers by study and by single nucleotide polymorphism (SNP)
Study Country
TP53 Arg72Pro
(rs1042522)
MDM2 309T4G
(rs2279744) Genotyping platform
Spanish National Cancer Centre (CNIO) Spain 788 0 Restriction enzyme digestion
Deutsches Krebsforschungszentrum (DKFZ) Germany 170 0 PCR-based RFLP
Epidemiological study of BRCA1 and BRCA2
mutation carriers (EMBRACE)
U.K. and Eire 1131 0 iPLEX
Genetic Modifiers of cancer risk in BRCA1/2
mutation carriers (GEMO)
France and U.S.A. 1405 1357 Taqman
German Consortium of Hereditary Breast and
Ovarian Cancer (GC-HBOC)
Germany 815 0 Taqman
Helsinki Breast Cancer Study (HEBCS) Finland 188 187 rs1042522: Amplifluor(tm) fluorescent
genotyping (Kbiosciences); rs2279744:
RFLP
HEreditary Breast and Ovarian study Netherlands
(HEBON)
The Netherlands 438 432 Taqman
INterdisciplinary HEalth Research International
Team BReast CAncer susceptibility (INHERIT
BRCAs)
Quebec-Canada 146 155 Taqman
kConFab Australia 790 0 iPLEX
National Cancer Institute (NCI) USA 190 0 Taqman
National Israeli Cancer Control Center (NICCC) Israel 470 0 Taqman
Ontario Cancer Genetics Network (OCGN) Canada 84 91 Taqman
University of Pennsylvania (UPENN) USA 396 0 iPLEX
Total 7011 2222
Table 2 Summary characteristics for the 7109 eligible BRCA1 and BRCA2
carriers used in the analysis and typed for either single nucleotide
polymorphism (SNP)
BRCA1 BRCA2
Characteristic Unaffected
Breast
cancer Unaffected
Breast
cancer
Number 2055 2567 1051 1436
Person-years follow-up 87571 104679 46315 63080
Median age at censure (IQR) 41 (33–51) 40 (34–46) 42 (34–52) 43 (37–50)
Age at censure (years), N (%)
o30 327 (15.9) 225 (8.8) 139 (13.2) 78 (5.4)
30–39 584 (28.4) 1052 (41.0) 296 (28.1) 462 (32.2)
40–49 574 (27.9) 880 (34.3) 286 (27.2) 511 (35.6)
50–59 364 (17.7) 296 (11.5) 196 (18.7) 278 (19.4)
60–69 134 (6.5) 87 (3.4) 82 (7.8) 81 (5.6)
70+ 72 (3.5) 27 (1.0) 52 (4.9) 26 (1.8)
Year of birth, N (%)
o1920 18 (0.9) 32 (1.3) 12 (1.1) 10 (0.7)
1920–29 63 (3.1) 117 (4.6) 39 (3.7) 83 (5.8)
1930–39 171 (8.3) 267 (10.4) 96 (9.1) 196 (13.7)
1940–49 326 (15.9) 657 (25.6) 143 (13.6) 358 (24.9)
1950–59 481 (23.4) 820 (31.9) 241 (22.9) 459 (32.0)
1960+ 996 (48.5) 674 (26.3) 520 (49.5) 330 (23.0)
Abbreviation: IQR¼interquartile range.
TP53 and MDM2 SNPs and BRCA1/2 breast cancer risk
OM Sinilnikova et al
1458
British Journal of Cancer (2009) 101(8), 1456–1460 & 2009 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sfor these SNPs suggest that they have little or no effect on BRCA-
related breast cancer risk. These results are consistent with the
absence of risk association in the recent TP53 haplotype analysis,
involving Arg72Pro and an intronic polymorphism c.97-
147ins16bp, in a series of 2932 BRCA1 and BRCA2 carriers from
CIMBA (Osorio et al, 2008). Our sample of mutation carriers had
power of approximately 75% for TP53 and 40% for MDM2 to
detect significant associations (Po0.05) for a per-allele HR of 1.1
and power of 100 and 90% respectively for a HR of 1.2, suggesting
that we can reliably dismiss previously suggested associations
(Martin et al, 2003; Osorio et al, 2006; Yarden et al, 2008).
Yarden et al showed that the MDM2 GG genotype among
Ashkenazi BRCA1/2 mutations carriers was significantly associated
with breast cancer diagnosed oage 51 (P¼0.019) (Yarden et al,
2008). However, we did not find any evidence of an increased risk
for the GG homozygotes among the 217 carriers of the BRCA1
Ashkenazi mutations 185delAG and 5382insC (HR¼0.98, 95%CI
0.48–2.01) in this series.
The BCAC study of 5191 cases and 3834 controls found no
evidence of an association of TP53 Arg72Pro and MDM2 309T4G
either with breast cancer overall or with oestrogen receptor (ER)
status of tumours (Schmidt et al, 2007). As the majority of BRCA1
mutation-associated breast tumours are ER-negative (Lakhani
et al, 2005), the absence of an association in our study of breast
cancer with the TP53 and MDM2 SNPs in BRCA1 mutation carriers
is consistent with the lack of an association with ER-negative
cancers in the general population.
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